.png){kind=small}
.png){kind=small}
BackTable / Tumor Board / Podcast / Episode #42
Neoadjuvant Therapy in Resectable Pancreatic Cancer
with Dr. Rebecca Snyder and Dr. Jonathan Mizrahi
For the small subset of pancreatic cancer patients whose cancer is detected early and remains localized, there are now opportunities to offer treatment and improve outcomes. In this episode of the BackTable Tumor Board Podcast, Ochsner medical oncologist Dr. Jonathan Mizrahi and MD Anderson surgical oncologist Dr. Rebecca Snyder discuss the contemporary management of localized pancreatic cancer.
Be part of the conversation. Put your sponsored messaging on this episode. Learn how.
BackTable, LLC (Producer). (2026, January 6). Ep. 42 – Neoadjuvant Therapy in Resectable Pancreatic Cancer [Audio podcast]. Retrieved from https://www.backtable.com
Stay Up To Date
Follow:
Subscribe:
Sign Up:
Podcast Contributors
Synopsis
Dr. Snyder and Dr. Mizrahi break down the categories of resectable, borderline resectable, and locally advanced pancreatic cancer; and explain the current treatment strategies that are tailored to each stage. The discussion highlights the role of neoadjuvant therapy, the potential benefits of radiation for certain subpopulations, and the importance of a multidisciplinary team approach for optimal patient care. The doctors also cover pivotal clinical trials, ongoing research, and future directions in the field, including targeted therapies and biomarker development, to inform best practices in treating patients with localized pancreatic cancer.
Timestamps
00:00 - Introduction
02:24 - Defining Resectable, Borderline, and Locally Advanced Pancreatic Cancer
11:10 - Neoadjuvant Therapy for Resectable Pancreatic Cancer
17:16 - Ongoing Clinical Trials: FOLFIRINOX and Gemcitabine Nab-Paclitaxel
23:04 - The Role of Radiation in Pancreatic Cancer Treatment
26:52 - Treating Locally Advanced Pancreatic Cancer
34:49 - Future Directions and Targeted Therapies
Resources
APOLLO Randomized Phase II Study
https://clinicaltrials.gov/study/NCT04858334
PRODIGE 29-UCGI 26 (NEOPAN) Phase III Trial
https://ascopubs.org/doi/10.1200/JCO-24-02210
ALLIANCE A021806 Phase III Trial
https://doi.org/10.1245/s10434-024-15817-5
NORPACT-1 Phase II Trial
https://pubmed.ncbi.nlm.nih.gov/38237621/
Dutch Randomized Phase III PREOPANC Trial
https://pubmed.ncbi.nlm.nih.gov/32105518/
SWOG S1505 Randomized Clinical Trial
https://pubmed.ncbi.nlm.nih.gov/32740235/
ALLIANCE A021501 Phase II Randomized Clinical Trial
https://pubmed.ncbi.nlm.nih.gov/35834226/
LAP07 Randomized Clinical Trial
https://pubmed.ncbi.nlm.nih.gov/27139057/
LAP100 Phase III Trial
https://clinicaltrials.gov/study/NCT06958328
Meta-analysis on Arterial Resections in Pancreatic Cancer
https://pmc.ncbi.nlm.nih.gov/articles/PMC12070998/
PANOVA-3 Phase III Study
https://ascopubs.org/doi/10.1200/JCO-25-00746
NRG-GI011 Clinical Trial: Opening
https://www.nrgoncology.org/patients/patient-study-webpages/nrg-gi011-testing-higher-dose-rt-for-locally-advanced-pancreatic-cancer
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.
Up Next
Articles
Topics
